Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-746-3 | CAS number: 693-23-2
Endpoint summary
Administrative data
Description of key information
Dodecandioic acid has been used experimentally in both parenteral and oral clinical alimentation studies. No adverse effects were reported at dose levels of up to 40g per person.
In an isolated case report occupational asthma was associated with exposure to soldering fumes from dodecanedioic acid containing flux.
Additional information
Dodecanedioic acid is rapidly and completely absorbed from the gastrointestinal tract. It is metabolised and incorporated in the fatty acid catabolism of the organism and has been proposed to be an intermediate in the beta-oxidation of long-chain fatty acids. Dodecanedioic acid is not or only to a small extent excreted renally. Dodecanedioic acid is devoid of any systemic adverse effects upon acute or repeated dosing. One single casuistic of occupational asthma was linked to exposure to decomposition fumes of dodecanedioic acid in soldering flux but the medical history of this isolated case is unclear.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
